Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database

References

• Bartus RT, Dean RLIII, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14.
   PubMed Web of Science ®Google Scholar
• Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000;163:495–529.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar A, Alzheimer’s disease therapy: present and future molecules. In: Kunal R, ed. Computational modeling of drugs against Alzheimer’s disease. New York: Humana Press; 2018:3–22.
   Google Scholar
• Ordentlich A, Barak D, Kronman C, et al. Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. J Biol Chem 1993;268:17083–95.
   PubMed Web of Science ®Google Scholar
• Ordentlich A, Barak D, Kronman C, et al. Functional characteristics of the oxyanion hole in human acetylcholinesterase. J Biol Chem 1998;273:19509–17.
   PubMed Web of Science ®Google Scholar
• Radic Z, Pickering NA, Vellom DC, et al. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993;32:12074–84.
   PubMed Web of Science ®Google Scholar
• Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991;253:872–9.
   PubMed Web of Science ®Google Scholar
• Carvajal FJ, Inestrosa NC. Interactions of AChE with Aβ aggregates in Alzheimer's brain: therapeutic relevance of IDN 5706. Front Mol Neurosci 2011;4:19.
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr Med Chem 2013;20:1662–72.
   PubMed Web of Science ®Google Scholar
• Viayna E, Sabate R, Muñoz-Torrero D. Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Curr Top Med Chem 2013;13:1820–42.
   PubMed Web of Science ®Google Scholar
• Rosini M, Simoni E, Minarini A, et al. Multi-target design strategies in the context of Alzheimer’s disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem Res 2014;39:1914–23.
   PubMed Web of Science ®Google Scholar
• Greenblatt HM, Guillou C, Guénard D, et al. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J Am Chem Soc 2004;126:15405–11.
   PubMed Web of Science ®Google Scholar
• Camps P, Formosa X, Galdeano C, et al. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem 2008;51:3588–98.
   PubMed Web of Science ®Google Scholar
• Jia P, Sheng R, Zhang J, et al. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors. Eur J Med Chem 2009;44:772–84.
   PubMed Web of Science ®Google Scholar
• Bartolucci C, Haller LA, Jordis U, et al. Probing torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives. J Med Chem 2010;53:745–51.
   PubMed Web of Science ®Google Scholar
• Kozurkova M, Hamulakova S, Gazova Z, et al. Neuroactive multifunctional tacrine congeners with cholinesterase, anti-amyloid aggregation and neuroprotective properties. Pharmaceuticals 2011;4:382–418.
   Google Scholar
• Scherzer-Attali R, Pellarin R, Convertino M, et al. Complete phenotypic recovery of an Alzheimer’s disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One 2010;5:e11101.
   PubMed Web of Science ®Google Scholar
• Bolea I, Juárez-Jiménez J, de Los Ríos C, et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J Med Chem 2011;54:8251–70.
   PubMed Web of Science ®Google Scholar
• Simoni E, Daniele S, Bottegoni G, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem 2012;55:9708–21.
   PubMed Web of Science ®Google Scholar
• Bautista-Aguilera OM, Esteban G, Chioua M, et al. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. Drug Des Devel Ther 2014;8:1893–910.
   PubMed Web of Science ®Google Scholar
• Wang L, Esteban G, Ojima M, et al. Donepezil + propagylamine +8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur J Med Chem 2014;80:543–61.
   PubMed Web of Science ®Google Scholar
• Nepovimova E, Uliassi E, Korabecny J, et al. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J Med Chem 2014;57:8576–89.
   PubMed Web of Science ®Google Scholar
• Korabecny J, Andrs M, Nepovimova E, et al. 7-Methoxytacrine-p-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer's disease treatment. Molecules 2015;20:22084–101.
   PubMed Web of Science ®Google Scholar
• Singh M, Kaur M, Chadha N, et al. Hybrids: a new paradigm to treat Alzheimer's disease. Mol Divers 2016;20:271–97.
   PubMed Web of Science ®Google Scholar
• Piazzi L, Rampa A, Bisi A, et al. 3-(4-{[Benzyl(methyl)amino] methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003;46:2279–82.
   PubMed Web of Science ®Google Scholar
• Hernández-Rodríguez M, Correa-Basurto J, Martínez-Ramos F, et al. Design of multi-target compounds as AChE, BACE1, and amyloid-β(1-42) oligomerization inhibitors: in silico and in vitro studies. J Alzheimers Dis 2014;41:1073–85.
   PubMed Web of Science ®Google Scholar
• Meena P, Nemaysh V, Khatri M, et al. Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer’s disease. Bioorg Med Chem 2015;23:1135–48.
   PubMed Web of Science ®Google Scholar
• Guzior N, Bajda M, Skrok M, et al. Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties. Eur J Med Chem 2015;92:738–49.
   PubMed Web of Science ®Google Scholar
• Basile L, Virtual screening in the search of new and potent anti-Alzheimer agents. In: Kunal R, ed. Computational modeling of drugs against Alzheimer’s disease. New York: Humana Press; 2018:107–137.
   Google Scholar
• Fradera X, Babaoglu K. Overview of methods and strategies for conducting virtual small molecule screening. Curr Protoc Chem Biol 2017;9:196–212.
   PubMedGoogle Scholar
• Chen Y, Fang L, Peng S, et al. Discovery of a novel acetylcholinesterase inhibitor by structure-based virtual screening techniques. Bioorg Med Chem Lett 2012;22:3181–7.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andreas V Jr, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Dhanjal JK, Sharma S, Grover A, et al. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's. Biomed Pharmacother 2015;71:146–52.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin H, Yang H, et al. Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structure-based virtual screening. RSC Adv 2017;7:3429–38.
   Web of Science ®Google Scholar
• Cheung J, Rudolph MJ, Burshteun F, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282–6.
   PubMed Web of Science ®Google Scholar
• Atanasova M, Yordanov N, Dimitrov I, et al. Molecular docking study on galantamine derivatives as cholinesterase inhibitors. Mol Inf 2015;34:394–403.
   PubMed Web of Science ®Google Scholar
• Atanasova M, Stavrakov G, Philipova I, et al. Galantamine derivatives with indole moiety: docking, design, synthesis and acetylcholinesterase activity. Bioorg Med Chem 2015;23:5382–9.
   PubMed Web of Science ®Google Scholar
• Stavrakov G, Philipova I, Zheleva D, et al. Docking-based design of galantamine derivatives with dual-site binding to acetylcholinesterase. Mol Inform 2016;35:278–85.
   PubMed Web of Science ®Google Scholar
• Stavrakov G, Philipova I, Zheleva-Dimitrova D, et al. Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase. Chem Biol Drug Des 2017;90:709–18.
   PubMed Web of Science ®Google Scholar
• Freyer MW, Lewis EA. Isothermal titration calorimery: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. In: Biophysical Tools for Biologists, volume one: In Vitro Techniques. Methods Cell Biol 2008;84:79–113.
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH, Fan K, et al. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003;38:223–32.
   PubMed Web of Science ®Google Scholar
• Momekov G, Ferdinandov D, Bakalova A, et al. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands. Arch Toxicol 2006;80:555–60.
   PubMed Web of Science ®Google Scholar
• Zhivkova Z, Doytchinova I. Quantitative structure – pharmacokinetics relationships analysis of basic drugs: volume of distribution. J Pharm Pharm Sci 2015;18:515–27.
   PubMed Web of Science ®Google Scholar
• Zhivkova Z. Quantitative structure – pharmacokinetics relationships for plasma protein binding of basic drugs. J Pharm Pharm Sci 2017;20:349–59.
   PubMed Web of Science ®Google Scholar
• Zhivkova Z, Doytchinova I. Quantitative structure – pharmacokinetic relationships for plasma clearance of basic drugs with consideration of the major elimination pathway. J Pharm Pharm Sci 2017;20:135–47.
   PubMed Web of Science ®Google Scholar
• Zhivkova Z. Quantitative structure – pharmacokinetics relationship for the steady state volume of distribution of basic and neutral drugs. World J Pharm Pharm Sci 2018;7:94–105.
   Google Scholar
• Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 2008;36:1385–405.
   PubMed Web of Science ®Google Scholar
• Berellini G, Waters NJ, Lombardo F. In silico prediction of total human plasma clearance. J Chem Inf Model 2012;52:2069–78.
   PubMed Web of Science ®Google Scholar
• Roy K, Kar S, Das RN, Statistical methods in QSAR/QSPR. In: Roy K, Kar S, Das RN, eds. A primer on QSAR/QSPR modeling. Fundamental concepts, Springer Briefs in Molecular Science. Cham: Springer; 2015:37–59.
   Google Scholar
• Zou Y, Li L, Chen W, et al. Virtual screening and structure-based discovery of indole acylguanidines as potent β-secretase (BACE1) inhibitors. Molecules 2013;18:5706–22.
   PubMed Web of Science ®Google Scholar
• Karasova JZ, Korabecny J, Zemek F, et al. Acetylcholinesterase inhibitors used or tested in Alzheimer’s disease therapy; their passive diffusion through blood brain barrier: in vitro study. Afr J Pharm Pharmacol 2013;7:1471–80.
   Google Scholar
• Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 2003;42:1383–92.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Interspecies variations in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980;8:165–76.
   PubMedGoogle Scholar
• Peters SA. Physiologically-Based Pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. Hoboken (NJ): John Wiley & Sons Inc; 2012:407–421.
   Google Scholar
• Lee NY, Kang YS. The inhibitory effect of rivastigmine and galantamine on choline transport in brain capillary endothelian cells. Biomol Ther 2010;18:65–70.
   Web of Science ®Google Scholar